ChristopherLMoertelMD

Pediatric Hematology & Oncology • Minneapolis, MN

Pediatric Neuro-Oncology

Professor, Pediatrics, University of Minnesota Medical School

Join to view full profile

Dr. Moertel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moertel's full profile

Already have an account?

Office
2450 Riverside Ave.
East Building, Ninth Floor
Minneapolis, MN 55454
Phone+1 612-365-8100

Fax+1 612-626-2815

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Pediatric Hematology/Oncology, 1987 - 1990
Baylor College of Medicine (Houston)Residency, Pediatrics, 1984 - 1986
University of Minnesota Medical SchoolClass of 1984

Certifications & Licensure

MN State Medical License 1987 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
ACTIVE_NOT_RECRUITING
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
ACTIVE_NOT_RECRUITING
PHASE3
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor Start of enrollment: 2010 Sep 01
Completed
Phase 1
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma Start of enrollment: 2012 Jul 17
Terminated
Phase 1
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Start of enrollment: 2022 Jun 20
Recruiting
Phase 2, Phase 3
Roles: Contact
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
ACTIVE_NOT_RECRUITING
PHASE4
Roles: Contact
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Start of enrollment: 2025 Jun 15
NOT_YET_RECRUITING
PHASE2
Roles: Contact
NF-1, Nutraceutical Intervention Start of enrollment: 2022 Jul 06
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Start of enrollment: 2021 Dec 15
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.
Audrey-Anne Lamoureux, Michael J Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani
Clinical Cancer Research. 2025-02-03
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors.
Kyle B Williams, Alex T Larsson, Bryant J Keller, Katherine E Chaney, Rory L Williams
Biorxiv. 2024-11-01

Press Mentions

FDA Approves Vimseltinib for Certain Symptomatic Tenosynovial Giant Cell TumorsFebruary 18th, 2025
FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZenecaFebruary 12th, 2025
FDA OKs Mirdametinib for Neurofibromatosis Type 1February 11th, 2025
Join now to see all